Suppr超能文献

利用蛋白酶激活进行治疗。

Exploiting protease activation for therapy.

机构信息

Research & Early Development, Cardiovascular, Renal & Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge, UK.

Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.

出版信息

Drug Discov Today. 2022 Jun;27(6):1743-1754. doi: 10.1016/j.drudis.2022.03.011. Epub 2022 Mar 18.

Abstract

Proteases have crucial roles in homeostasis and disease; and protease inhibitors and recombinant proteases in enzyme replacement therapy have become key therapeutic applications of protease biology across several indications. This review briefly summarises therapeutic approaches based on protease activation and focuses on how recent insights into the spatial and temporal control of the proteolytic activation of growth factors and interleukins are leading to unique strategies for the discovery of new medicines. In particular, two emerging areas are covered: the first is based on antibody therapies that target the process of proteolytic activation of the pro-form of proteins rather than their mature form; the second covers a potentially new class of biopharmaceuticals using engineered, proteolytically activable and initially inactive pro-forms of antibodies or effector proteins to increase specificity and improve the therapeutic window.

摘要

蛋白酶在体内平衡和疾病中起着至关重要的作用;蛋白酶抑制剂和重组蛋白酶在酶替代疗法中已成为蛋白酶生物学在多个适应症中的关键治疗应用。本文简要总结了基于蛋白酶激活的治疗方法,并重点介绍了最近对生长因子和白细胞介素的蛋白水解激活的时空控制的深入了解如何为发现新药带来独特的策略。特别是,涵盖了两个新兴领域:第一个基于抗体疗法,该疗法针对蛋白质前体形式的蛋白水解激活过程,而不是其成熟形式;第二个涵盖了一类潜在的新型生物制药,使用经过工程设计的、可蛋白水解激活的、最初无活性的抗体或效应蛋白前体形式,以提高特异性并改善治疗窗口。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2236/9132161/1068281aa220/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验